PubRank

S L Morrison

Author PubWeight™ 192.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell 1983 18.86
2 Detection of specific hybridoma clones by replica immunoadsorption of their secreted antibodies. Proc Natl Acad Sci U S A 1979 13.60
3 Natural history of acute coronary heart attacks. A community study. Br Heart J 1972 8.55
4 Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci U S A 1983 5.18
5 Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984 3.32
6 Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989 2.42
7 Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988 2.40
8 Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997 2.13
9 Natural history of unstable angina. Lancet 1972 2.03
10 A quantitative difference in the immune response between male and female mice. Proc Soc Exp Biol Med 1968 1.90
11 The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991 1.88
12 Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995 1.87
13 Polypeptide products of nonsense mutations. I. Termination fragments from nonsense mutations in the Z gene of the lac operon of Escherichia coli. J Mol Biol 1970 1.84
14 Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992 1.74
15 Heavy chain-producing variants of a mouse myeloma cell line. J Immunol 1975 1.73
16 Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993 1.73
17 Prognosis of new and worsening angina pectoris. Br Med J 1976 1.59
18 Murine heavy chain disease. Eur J Immunol 1978 1.50
19 A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors. Anal Biochem 1991 1.40
20 Estimation of antibodies specific for dextran. J Immunol 1978 1.38
21 Production and properties of chimeric antibody molecules. Methods Enzymol 1989 1.35
22 Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. J Immunol 1986 1.34
23 Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997 1.32
24 Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 2000 1.31
25 Characterization of the J chain from polymeric immunoglobulins (IgA-IgM-immunological specificity-primary structure). Proc Natl Acad Sci U S A 1972 1.31
26 Regulation of immunoglobulin expression in mouse myeloma cells. Cold Spring Harb Symp Quant Biol 1977 1.28
27 Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans. J Immunol 1987 1.27
28 Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci U S A 1990 1.26
29 Myeloma mutant with a novel 3' flanking region: loss of normal sequence and insertion of repetitive elements leads to decreased transcription but normal processing of the alpha heavy-chain gene products. Mol Cell Biol 1986 1.21
30 Transfectomas provide novel chimeric antibodies. Science 1985 1.20
31 Policy for early discharge after acute myocardial infarction. Br Med J 1980 1.19
32 Bone-marrow suppression associated with cimetidine. Ann Intern Med 1979 1.17
33 Sequentially derived mutants of the constant region of the heavy chain of murine immunoglobulins. J Immunol 1979 1.16
34 Sequences near the 3' secretion-specific polyadenylation site influence levels of secretion-specific and membrane-specific IgG2b mRNA in myeloma cells. Mol Cell Biol 1986 1.16
35 Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994 1.16
36 Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 1998 1.15
37 Transfer and expression of immunoglobulin genes. Annu Rev Immunol 1984 1.15
38 Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci U S A 1987 1.15
39 Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J Biol Chem 1999 1.14
40 Enhanced immunologic sensitization of mice by the simultaneous injection of antigen and specific antiserum. II. Effect of varying the antigen-antibody ratio and the amount of immune complex injected. J Immunol 1966 1.14
41 Two alpha heavy chain disease proteins with different genomic deletions demonstrate that nonexpressed alpha heavy chain genes contain methylated bases. Proc Natl Acad Sci U S A 1981 1.13
42 Immunochemical characterization of binding sites of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran. Mol Immunol 1982 1.12
43 The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med 1991 1.12
44 Loss of a consensus splice signal in a mutant immunoglobulin gene eliminates the CH1 domain exon from the mRNA. Mol Cell Biol 1984 1.09
45 Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J 1991 1.09
46 Ultraviolet-Stimulated KHCO(3) Efflux from Rose Cells: Regulation of Cytoplasmic pH. Plant Physiol 1983 1.09
47 The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med 2000 1.06
48 Association constants of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran determined by affinity electrophoresis. Mol Immunol 1982 1.05
49 The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 1994 1.05
50 Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen. J Exp Med 1988 1.03
51 Production and characterization of monoclonal antibodies to the subunits of human phosphofructokinase: new tools for the immunochemical and genetic analyses of isozymes. Blood 1981 1.01
52 Developmental regulation of membrane and secretory Ig gamma 2b mRNA. J Immunol 1989 1.01
53 The identification of mouse myeloma cells which have undergone mutations in immunoglobulin production. Soc Gen Physiol Ser 1974 1.01
54 Studies on mouse hybridomas secreting IgM or IgA antibodies to alpha(1 to 6)-linked dextran. Mol Immunol 1981 1.01
55 Mutational events in mouse myeloma cells. Crit Rev Immunol 1981 0.99
56 Sequences of variable regions of hybridoma antibodies to alpha (1----6) dextran in BALB/c and C57BL/6 mice. J Immunol 1985 0.98
57 Expression of a VHC kappa chimaeric protein in mouse myeloma cells. Nature 1984 0.98
58 Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci U S A 1995 0.98
59 Somatically generated mouse myeloma variants synthesizing IgA half-molecules. J Exp Med 1981 0.97
60 Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc Natl Acad Sci U S A 1992 0.97
61 Mapping studies reveal unique epitopes on IgG recognized by rheumatoid arthritis-derived monoclonal rheumatoid factors. J Immunol 1993 0.96
62 Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 1999 0.96
63 An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J Immunol 1999 0.96
64 Production of secretory immunoglobulin A by a single mammalian cell. Proc Natl Acad Sci U S A 1997 0.96
65 Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. J Immunol Methods 1993 0.95
66 In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 1999 0.95
67 Appearance of an early "primed state" in mice following the concomitant injections of antigen and specific antiserum. J Immunol 1972 0.95
68 A common sequence motif near nonhomologous recombination breakpoints involving Ig sequences. J Immunol 1993 0.93
69 Divergence of human alpha-chain constant region gene sequences. A novel recombinant alpha 2 gene. J Immunol 1994 0.93
70 Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function. J Immunol 1997 0.93
71 Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res 1998 0.93
72 A variant of the dextran-binding mouse plasmacytoma J558 with altered glycosylation of its heavy chain and decreased reactivity with polymeric dextran. Biochemistry 1981 0.93
73 Formation of hybridoma clones in soft agarose: effect of pH and of medium. Somatic Cell Genet 1980 0.93
74 Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000 0.92
75 Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol Immunol 1994 0.92
76 Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody. J Immunol 1999 0.92
77 Structural requirements for polymeric immunoglobulin assembly and association with J chain. J Biol Chem 1999 0.91
78 Alternative splicing patterns in an aberrantly rearranged immunoglobulin kappa-light-chain gene. Proc Natl Acad Sci U S A 1985 0.91
79 Chimeric antibodies with 17-1A-derived variable and human constant regions. Hybridoma 1986 0.91
80 Residues critical for H-L disulfide bond formation in human IgA1 and IgA2. J Immunol 1996 0.91
81 Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res 1993 0.89
82 Site-specific and directional gene replacement mediated by Cre recombinase. J Immunol Methods 2000 0.87
83 Identification and characterization of a myristylated and palmitylated serine/threonine protein kinase. Biochem Biophys Res Commun 1999 0.87
84 Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol 1997 0.86
85 Recombinant polymeric IgG: an approach to engineering more potent antibodies. Biotechnology (N Y) 1994 0.85
86 Polypeptide products of nonsense mutations. II. Minor fragments produced by nonsense mutations in the z gene of the lactose operon of Escherichia coli. J Mol Biol 1971 0.85
87 Repair of postcatheterization femoral pseudoaneurysms by color flow ultrasound guided compression. Am Heart J 1992 0.85
88 Heavy-chain mutants derived from gamma 2b mouse myeloma: characterization of heavy-chain messenger ribonucleic acid, proteins, and secretion in delection mutants and messenger ribonucleic acid in gamma2a mutant progeny. Biochemistry 1981 0.85
89 Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem 2001 0.85
90 An analysis of heavy chain glycopeptides of hybridoma antibodies: correlation between antibody specificity and sialic acid content. J Immunol 1981 0.84
91 Psychological, topographic EEG, and CT scan correlates of frontal lobe function in schizophrenia. Psychiatry Res 1989 0.84
92 Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin Exp Med 2004 0.84
93 Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J Immunol 1995 0.83
94 ICR-191 and ethyl methanesulfonate induced mutagenesis at the immunoglobulin locus in the Y5606 cultured myeloma cell line. Mutat Res 1981 0.83
95 Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 1992 0.83
96 Isolation and characterization of a variant of mouse plasmacytoma J558 synthesizing a 110,000-dalton immunoglobulin heavy chain and of secondary variants synthesizing either a 55,000-dalton or an 80,000-dalton immunoglobulin heavy chain: possible implications. Mol Cell Biol 1982 0.83
97 Enhanced immunologic sensitization of mice by the simultaneous injection of antigen and specific antiserum. 3. The role of antigen in controlling the immune response elicited with immune complexes. J Immunol 1967 0.83
98 A colorimetric-enzymatic microassay for the quantitation of antibody-dependent complement activation. J Immunol Methods 1999 0.83
99 Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. Clin Immunol 2001 0.82
100 A mouse myeloma variant with a defect in light chain synthesis. Eur J Immunol 1979 0.82
101 The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J Immunol 1997 0.82
102 Amino acid substitutions in VH CDR2 change the idiotype but not the antigen-binding of monoclonal antibodies to alpha(1----6)dextrans. J Immunol 1989 0.82
103 Specificity and variable region cDNA sequence of an isogeneic monoclonal antiidiotype to an anti-alpha(1----6)dextran. Mol Immunol 1991 0.82
104 A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies 2001 0.82
105 In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J Immunol 1996 0.81
106 Molecular analysis of IgM rheumatoid factor binding to chimeric IgG. J Immunol 1991 0.81
107 Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting. Proc Natl Acad Sci U S A 1990 0.81
108 A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol 1998 0.81
109 Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001 0.81
110 Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement. Mol Immunol 1997 0.81
111 Mapping IgG epitopes bound by rheumatoid factors from immunized controls identifies disease-specific rheumatoid factors produced by patients with rheumatoid arthritis. J Immunol 1998 0.80
112 A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells. J Immunol 1985 0.80
113 Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin Immunol 2002 0.80
114 A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 1999 0.80
115 Functional properties of antibody insulin-like growth factor fusion proteins. J Biol Chem 1994 0.80
116 Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol 1994 0.80
117 Antibody variable region glycosylation: biochemical and clinical effects. Springer Semin Immunopathol 1993 0.80
118 Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains. Mol Immunol 1995 0.79
119 Biochemical characterization of a differentiation antigen shared by human epidermal langerhans cells and cortical thymocytes. J Clin Immunol 1982 0.79
120 Regulation of the production of secretory and membrane immunoglobulin during lymphocyte development. Clin Immunol Immunopathol 1989 0.78
121 An immunoglobulin heavy chain gene deletion at direct repeats: nucleotide sequence and effect on mRNA accumulation. Mol Immunol 1988 0.78
122 A cross-reactive idiotype, QUPC52 IdX, present on most but not all anti-alpha (1 replaced by 6) dextran-specific IgM and IgA hybridoma antibodies with combining sites of different sizes. J Immunol 1982 0.78
123 A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity. Cancer Immunol Immunother 2001 0.78
124 Expression of novel secreted isoforms of human immunoglobulin E proteins. J Biol Chem 1996 0.78
125 The role of carbohydrate in the assembly and function of polymeric IgG. Mol Immunol 2000 0.78
126 Effectiveness of topical non-steroidal anti-inflammatory drugs in the management of breast pain. J R Coll Surg Edinb 1998 0.77
127 C57BL/6 x BALB/c hybridomas produce IgA which assembles into molecules with covalent bonds between heavy chains (H) and light chains (L), and into molecules lacking covalent bonds between H and L. Mol Immunol 1985 0.77
128 Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J Neurosci Res 1997 0.77
129 Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). J Interferon Cytokine Res 2001 0.77
130 The effect of isotype and the J kappa region on antigen binding and idiotype expression by antibodies binding alpha (1----6) dextran. J Immunol 1989 0.77
131 Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 2000 0.77
132 Two Ig framework I epitopic specificities recognized by a rabbit antiserum and a monoclonal antibody to mouse VH chains. J Immunol 1990 0.77
133 Antibody-IL-2 fusion proteins: a novel strategy for immune protection. Hum Antibodies 1997 0.76
134 Structure-function studies of anti-3-fucosyllactosamine (Le(x)) and galactosylgloboside antibodies. J Immunol 1994 0.76
135 Recombinant chimeric monoclonal antibodies. Important Adv Oncol 1990 0.76
136 Sequences 3' of immunoglobulin heavy chain genes influence their expression. Immunol Rev 1986 0.76
137 Production and characterization of a murine/human chimeric anti-idiotype antibody that mimics ganglioside. Cancer Res 1992 0.76
138 Production and characterization of recombinant IgA. Immunotechnology 1999 0.76
139 Structure and function of several anti-dansyl chimeric antibodies formed by domain interchanges between human IgM and mouse IgG2b. J Biol Chem 1995 0.76
140 The novel human IgE epsilon heavy chain, epsilon tailpiece, is present in plasma as part of a covalent complex. Mol Immunol 2000 0.76
141 Mapping rheumatoid factor binding sites using genetically engineered, chimeric IgG antibodies. DNA Cell Biol 1992 0.76
142 A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol 1998 0.76
143 Immunology. Success in specification. Nature 1994 0.75
144 An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. J Interferon Cytokine Res 1998 0.75
145 The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications. West J Med 1992 0.75
146 Spontaneous deletions in Ig heavy chain genes: flanking sequences influence splice site selection. Nucleic Acids Res 1991 0.75
147 Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization. Proc Natl Acad Sci U S A 1998 0.75
148 The plasmacytoma J558L lacks constitutively active NF-kappa B and is deficient in early response gene activation. Nucleic Acids Res 1991 0.75
149 An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1995 0.75
150 An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: real time measurement of ligand binding. Mol Immunol 1996 0.75
151 Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Hybridoma 1994 0.75
152 Biomedical engineering--priorities for research in external aids. J Biomed Eng 1981 0.75
153 Gingival response to subgingival placement of monolithic tetracycline-impregnated fibers: microscopic observations. Int J Periodontics Restorative Dent 1993 0.75
154 Genetically-engineered antibodies: tools for the study of diverse properties of the antibody molecule. Immunol Rev 1992 0.75
155 The specificity of synovial IgM rheumatoid factors (RF) for genetically engineered IgG antibodies is not affected by the method used to immortalize RF-producing B cells. Scand J Immunol 1999 0.75
156 Production of novel immunoglobulin molecules by gene transfection. Mt Sinai J Med 1986 0.75
157 Social medicine. Lancet 1969 0.75
158 The prospect of the Medical Officer of Health seen from the university. R Inst Public Health Hyg J 1968 0.75
159 Both VH and VL regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM3. Cell Biophys 1994 0.75
160 Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein. Arch Virol 1994 0.75
161 Structural and functional properties of mouse-human chimeric IgD. Hum Antibodies Hybridomas 1992 0.75
162 Engineering novel antibody molecules. Chem Immunol 1997 0.75
163 Expression of genes containing the IgH enhancer in non-lymphoid cells. Mol Immunol 1990 0.75
164 Sequence of the gamma 2b membrane 3' untranslated region: polya site determination and comparison to the gamma 2a membrane 3' untranslated region. Mol Immunol 1992 0.75
165 Hybrid antibodies. Int Rev Immunol 1993 0.75
166 The IgA myeloma W3129 contains a deletion in CH3 which prevents the formation of the membrane form of heavy chain mRNA. Mol Immunol 1988 0.75
167 Social medicine and public health. Proc R Soc Med 1969 0.75
168 Intron sequences determine the expression of kappa light chain genes. Mol Immunol 1994 0.75
169 Rabbit antisera to the variable region domains of an anti-alpha(1----6) dextran using E. coli-produced VL and VH fusion proteins as immunogens. J Immunol Methods 1990 0.75
170 Identification and functional characterization of a highly conserved sequence in the intron of the kappa light chain gene. Mol Immunol 1996 0.75
171 Social medicine and management. Lancet 1967 0.75
172 "The safety of oral contraceptives". A case study in medical administration. Lancet 1967 0.75
173 The identification of priority areas for research in the external aids field of biomedical engineering. Int J Rehabil Res 1979 0.75
174 An insertion-deletion event in murine immunoglobulin kappa gene resembles mutations at heavy-chain disease loci. Somat Cell Mol Genet 1993 0.75